Pfizer agrees to pay $345 million to settle out of EpiPen antitrust case
MLex Summary: Pfizer has agreed to pay $345 million to settled consumer plaintiffs’ claims that it conspired to delay generic EpiPen competition. The agreement is still subject to US court approval....To view the full article, register now.
Already a subscriber? Click here to view full article